[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHueA6S81Ao9IsnB5w19uDC5iMIMREDZO74b5Dq4PzVs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":57,"rows":64},"Universität des Saarlandes",[4],65,false,14,6,159062,11,49,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Covid19",2,{"name":18,"count":16},"Health Status",{"name":20,"count":16},"Stress",{"name":22,"count":16},"Obesity",{"name":24,"count":16},"Injury",{"name":26,"count":16},"Acute Decompensated Heart Failure",{"name":28,"count":16},"Parkinson´s Disease",{"name":30,"count":16},"Parkinson Disease",[32,37,42,47,52],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06453577","Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure","2025-12-31","Recompensation",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05433116","Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC","2026-01","Pembrolizumab",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06223711","Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC","2027-03","durvalumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05820841","Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","2028-04","R-miniCHOP + Acalabrutinib",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT07026474","Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","2032-12","Cisplatin",[58,59,60,61,62,63],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[65,103,121,139,157,175,199,217,235,258,276,296,323,341,368,411,429,447,475,493,511,529,547,565,583,601,619,645,663,688,712,739,766],{"intervention":41,"totalTrials":16,"cells":66},{"EARLY_PHASE1":67,"PHASE1":70,"PHASE2":72,"PHASE3":85,"PHASE4":99,"NA":101},{"trials":68,"activeCount":69},[],0,{"trials":71,"activeCount":69},[],{"trials":73,"activeCount":84,"soonestReadout":40},[74],{"nctId":38,"briefTitle":39,"status":75,"phases":76,"primaryCompletion":40,"completion":77,"start":78,"enrollment":79,"conditions":80,"interventions":82},"ACTIVE_NOT_RECRUITING",[60],"2027-01","2023-05-25",50,[81],"Head and Neck Squamous Cell Carcinoma",[41,83],"Lenvatinib",1,{"trials":86,"activeCount":84,"soonestReadout":55},[87],{"nctId":53,"briefTitle":54,"status":88,"phases":89,"primaryCompletion":55,"completion":90,"start":91,"enrollment":92,"conditions":93,"interventions":95},"RECRUITING",[61],"2032-12-31","2025-10-30",214,[94],"Recurrent Head and Neck Squamous Cell Carcinoma",[56,41,96,97,98,41],"cisplatin + 5-fluorouracil","Alternative medications: carboplatin + 5-fluorouracil","Alternative medications: carboplatin",{"trials":100,"activeCount":69},[],{"trials":102,"activeCount":69},[],{"intervention":56,"totalTrials":84,"cells":104},{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":117,"NA":119},{"trials":106,"activeCount":69},[],{"trials":108,"activeCount":69},[],{"trials":110,"activeCount":69},[],{"trials":112,"activeCount":84,"soonestReadout":55},[113],{"nctId":53,"briefTitle":54,"status":88,"phases":114,"primaryCompletion":55,"completion":90,"start":91,"enrollment":92,"conditions":115,"interventions":116},[61],[94],[56,41,96,97,98,41],{"trials":118,"activeCount":69},[],{"trials":120,"activeCount":69},[],{"intervention":96,"totalTrials":84,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":135,"NA":137},{"trials":124,"activeCount":69},[],{"trials":126,"activeCount":69},[],{"trials":128,"activeCount":69},[],{"trials":130,"activeCount":84,"soonestReadout":55},[131],{"nctId":53,"briefTitle":54,"status":88,"phases":132,"primaryCompletion":55,"completion":90,"start":91,"enrollment":92,"conditions":133,"interventions":134},[61],[94],[56,41,96,97,98,41],{"trials":136,"activeCount":69},[],{"trials":138,"activeCount":69},[],{"intervention":97,"totalTrials":84,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":153,"NA":155},{"trials":142,"activeCount":69},[],{"trials":144,"activeCount":69},[],{"trials":146,"activeCount":69},[],{"trials":148,"activeCount":84,"soonestReadout":55},[149],{"nctId":53,"briefTitle":54,"status":88,"phases":150,"primaryCompletion":55,"completion":90,"start":91,"enrollment":92,"conditions":151,"interventions":152},[61],[94],[56,41,96,97,98,41],{"trials":154,"activeCount":69},[],{"trials":156,"activeCount":69},[],{"intervention":98,"totalTrials":84,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":171,"NA":173},{"trials":160,"activeCount":69},[],{"trials":162,"activeCount":69},[],{"trials":164,"activeCount":69},[],{"trials":166,"activeCount":84,"soonestReadout":55},[167],{"nctId":53,"briefTitle":54,"status":88,"phases":168,"primaryCompletion":55,"completion":90,"start":91,"enrollment":92,"conditions":169,"interventions":170},[61],[94],[56,41,96,97,98,41],{"trials":172,"activeCount":69},[],{"trials":174,"activeCount":69},[],{"intervention":51,"totalTrials":84,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":195,"NA":197},{"trials":178,"activeCount":69},[],{"trials":180,"activeCount":69},[],{"trials":182,"activeCount":69},[],{"trials":184,"activeCount":84,"soonestReadout":50},[185],{"nctId":48,"briefTitle":49,"status":88,"phases":186,"primaryCompletion":50,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":193},[61],"2028-12","2023-06-07",330,[191,192],"Large B-cell Lymphoma","Diffuse Large B Cell Lymphoma",[51,194],"R-miniCHOP",{"trials":196,"activeCount":69},[],{"trials":198,"activeCount":69},[],{"intervention":194,"totalTrials":84,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":213,"NA":215},{"trials":202,"activeCount":69},[],{"trials":204,"activeCount":69},[],{"trials":206,"activeCount":69},[],{"trials":208,"activeCount":84,"soonestReadout":50},[209],{"nctId":48,"briefTitle":49,"status":88,"phases":210,"primaryCompletion":50,"completion":187,"start":188,"enrollment":189,"conditions":211,"interventions":212},[61],[191,192],[51,194],{"trials":214,"activeCount":69},[],{"trials":216,"activeCount":69},[],{"intervention":83,"totalTrials":84,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":229,"PHASE4":231,"NA":233},{"trials":220,"activeCount":69},[],{"trials":222,"activeCount":69},[],{"trials":224,"activeCount":84,"soonestReadout":40},[225],{"nctId":38,"briefTitle":39,"status":75,"phases":226,"primaryCompletion":40,"completion":77,"start":78,"enrollment":79,"conditions":227,"interventions":228},[60],[81],[41,83],{"trials":230,"activeCount":69},[],{"trials":232,"activeCount":69},[],{"trials":234,"activeCount":69},[],{"intervention":46,"totalTrials":84,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":252,"PHASE4":254,"NA":256},{"trials":238,"activeCount":69},[],{"trials":240,"activeCount":69},[],{"trials":242,"activeCount":84,"soonestReadout":45},[243],{"nctId":43,"briefTitle":44,"status":88,"phases":244,"primaryCompletion":45,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},[60],"2027-12","2023-10-06",43,[249],"Extensive-stage Small-cell Lung Cancer",[46,251],"Chemotherapy",{"trials":253,"activeCount":69},[],{"trials":255,"activeCount":69},[],{"trials":257,"activeCount":69},[],{"intervention":251,"totalTrials":84,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":261,"activeCount":69},[],{"trials":263,"activeCount":69},[],{"trials":265,"activeCount":84,"soonestReadout":45},[266],{"nctId":43,"briefTitle":44,"status":88,"phases":267,"primaryCompletion":45,"completion":245,"start":246,"enrollment":247,"conditions":268,"interventions":269},[60],[249],[46,251],{"trials":271,"activeCount":69},[],{"trials":273,"activeCount":69},[],{"trials":275,"activeCount":69},[],{"intervention":36,"totalTrials":84,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":288},{"trials":279,"activeCount":69},[],{"trials":281,"activeCount":69},[],{"trials":283,"activeCount":69},[],{"trials":285,"activeCount":69},[],{"trials":287,"activeCount":69},[],{"trials":289,"activeCount":84,"soonestReadout":35},[290],{"nctId":33,"briefTitle":34,"status":75,"phases":291,"primaryCompletion":35,"completion":35,"start":292,"enrollment":293,"conditions":294,"interventions":295},[],"2023-05-01",12,[26],[36],{"intervention":297,"totalTrials":84,"cells":298},"Iron Isomaltoside 1000",{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":321},{"trials":300,"activeCount":69},[],{"trials":302,"activeCount":69},[],{"trials":304,"activeCount":69},[],{"trials":306,"activeCount":69},[],{"trials":308,"activeCount":69},[309],{"nctId":310,"briefTitle":311,"status":312,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":319},"NCT02905539","A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer","COMPLETED",[62],"2020-06","2016-07",26,[318],"Anemia, Iron-Deficiency",[297,320],"Ferric Carboxymaltose",{"trials":322,"activeCount":69},[],{"intervention":320,"totalTrials":84,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":339},{"trials":326,"activeCount":69},[],{"trials":328,"activeCount":69},[],{"trials":330,"activeCount":69},[],{"trials":332,"activeCount":69},[],{"trials":334,"activeCount":69},[335],{"nctId":310,"briefTitle":311,"status":312,"phases":336,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":337,"interventions":338},[62],[318],[297,320],{"trials":340,"activeCount":69},[],{"intervention":342,"totalTrials":84,"cells":343},"Influenza Vaccination",{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":366},{"trials":345,"activeCount":69},[],{"trials":347,"activeCount":69},[],{"trials":349,"activeCount":69},[],{"trials":351,"activeCount":69},[],{"trials":353,"activeCount":69},[354],{"nctId":355,"briefTitle":356,"status":312,"phases":357,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":365},"NCT03654937","Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes",[62],"2016-12-31","2018-04-01","2016-09-01",45,[363,364],"Influenza Virus Vaccine Adverse Reaction","Influenza Vaccine Allergy",[342],{"trials":367,"activeCount":69},[],{"intervention":369,"totalTrials":16,"cells":370},"Rituximab",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":393,"PHASE4":407,"NA":409},{"trials":372,"activeCount":69},[],{"trials":374,"activeCount":69},[],{"trials":376,"activeCount":69},[377],{"nctId":378,"briefTitle":379,"status":312,"phases":380,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":386},"NCT00726700","Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma",[60],"2012-02","2004-05",109,[385],"Lymphoma",[387,388,389,390,391,392],"pegfilgrastim","rituximab","cyclophosphamide","doxorubicin hydrochloride","prednisone","vincristine sulfate",{"trials":394,"activeCount":69},[395],{"nctId":396,"briefTitle":397,"status":312,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":404},"NCT03366272","Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r\u002Fr Elderly Lymphoma Patients",[60,61],"2025-01-15","2017-12-05",348,[403],"Lymphoma, Non-Hodgkin",[405,369,406],"Nivolumab","Gemcitabine",{"trials":408,"activeCount":69},[],{"trials":410,"activeCount":69},[],{"intervention":405,"totalTrials":84,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":425,"NA":427},{"trials":414,"activeCount":69},[],{"trials":416,"activeCount":69},[],{"trials":418,"activeCount":69},[],{"trials":420,"activeCount":69},[421],{"nctId":396,"briefTitle":397,"status":312,"phases":422,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":423,"interventions":424},[60,61],[403],[405,369,406],{"trials":426,"activeCount":69},[],{"trials":428,"activeCount":69},[],{"intervention":406,"totalTrials":84,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":443,"NA":445},{"trials":432,"activeCount":69},[],{"trials":434,"activeCount":69},[],{"trials":436,"activeCount":69},[],{"trials":438,"activeCount":69},[439],{"nctId":396,"briefTitle":397,"status":312,"phases":440,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":441,"interventions":442},[60,61],[403],[405,369,406],{"trials":444,"activeCount":69},[],{"trials":446,"activeCount":69},[],{"intervention":448,"totalTrials":84,"cells":449},"Conventional Vincristine",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":471,"NA":473},{"trials":451,"activeCount":69},[],{"trials":453,"activeCount":69},[],{"trials":455,"activeCount":69},[],{"trials":457,"activeCount":69},[458],{"nctId":459,"briefTitle":460,"status":312,"phases":461,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":467},"NCT01478542","OPTIMAL>60 \u002F DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine",[61],"2024-01-18","2011-11",1152,[466],"CD20+ Aggressive B-Cell Lymphoma",[448,468,469,470],"Liposomal Vincristine","Ricover-scheme rituximab","optimised rituximab-schedule",{"trials":472,"activeCount":69},[],{"trials":474,"activeCount":69},[],{"intervention":468,"totalTrials":84,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":489,"NA":491},{"trials":478,"activeCount":69},[],{"trials":480,"activeCount":69},[],{"trials":482,"activeCount":69},[],{"trials":484,"activeCount":69},[485],{"nctId":459,"briefTitle":460,"status":312,"phases":486,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":487,"interventions":488},[61],[466],[448,468,469,470],{"trials":490,"activeCount":69},[],{"trials":492,"activeCount":69},[],{"intervention":469,"totalTrials":84,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":507,"NA":509},{"trials":496,"activeCount":69},[],{"trials":498,"activeCount":69},[],{"trials":500,"activeCount":69},[],{"trials":502,"activeCount":69},[503],{"nctId":459,"briefTitle":460,"status":312,"phases":504,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":505,"interventions":506},[61],[466],[448,468,469,470],{"trials":508,"activeCount":69},[],{"trials":510,"activeCount":69},[],{"intervention":470,"totalTrials":84,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":525,"NA":527},{"trials":514,"activeCount":69},[],{"trials":516,"activeCount":69},[],{"trials":518,"activeCount":69},[],{"trials":520,"activeCount":69},[521],{"nctId":459,"briefTitle":460,"status":312,"phases":522,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":523,"interventions":524},[61],[466],[448,468,469,470],{"trials":526,"activeCount":69},[],{"trials":528,"activeCount":69},[],{"intervention":387,"totalTrials":84,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":541,"PHASE4":543,"NA":545},{"trials":532,"activeCount":69},[],{"trials":534,"activeCount":69},[],{"trials":536,"activeCount":69},[537],{"nctId":378,"briefTitle":379,"status":312,"phases":538,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":539,"interventions":540},[60],[385],[387,388,389,390,391,392],{"trials":542,"activeCount":69},[],{"trials":544,"activeCount":69},[],{"trials":546,"activeCount":69},[],{"intervention":389,"totalTrials":84,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":550,"activeCount":69},[],{"trials":552,"activeCount":69},[],{"trials":554,"activeCount":69},[555],{"nctId":378,"briefTitle":379,"status":312,"phases":556,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":557,"interventions":558},[60],[385],[387,388,389,390,391,392],{"trials":560,"activeCount":69},[],{"trials":562,"activeCount":69},[],{"trials":564,"activeCount":69},[],{"intervention":390,"totalTrials":84,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":568,"activeCount":69},[],{"trials":570,"activeCount":69},[],{"trials":572,"activeCount":69},[573],{"nctId":378,"briefTitle":379,"status":312,"phases":574,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":575,"interventions":576},[60],[385],[387,388,389,390,391,392],{"trials":578,"activeCount":69},[],{"trials":580,"activeCount":69},[],{"trials":582,"activeCount":69},[],{"intervention":391,"totalTrials":84,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":595,"PHASE4":597,"NA":599},{"trials":586,"activeCount":69},[],{"trials":588,"activeCount":69},[],{"trials":590,"activeCount":69},[591],{"nctId":378,"briefTitle":379,"status":312,"phases":592,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":593,"interventions":594},[60],[385],[387,388,389,390,391,392],{"trials":596,"activeCount":69},[],{"trials":598,"activeCount":69},[],{"trials":600,"activeCount":69},[],{"intervention":392,"totalTrials":84,"cells":602},{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":613,"PHASE4":615,"NA":617},{"trials":604,"activeCount":69},[],{"trials":606,"activeCount":69},[],{"trials":608,"activeCount":69},[609],{"nctId":378,"briefTitle":379,"status":312,"phases":610,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":611,"interventions":612},[60],[385],[387,388,389,390,391,392],{"trials":614,"activeCount":69},[],{"trials":616,"activeCount":69},[],{"trials":618,"activeCount":69},[],{"intervention":620,"totalTrials":84,"cells":621},"abiraterone acetate + prednisone + LHRH-therapy",{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":623,"activeCount":69},[],{"trials":625,"activeCount":69},[],{"trials":627,"activeCount":69},[628],{"nctId":629,"briefTitle":630,"status":312,"phases":631,"primaryCompletion":632,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":637},"NCT02077634","Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)",[60],"2019-04-01","2014-05",68,[636],"Prostate Cancer",[620,638],"abiraterone acetate + prednisone",{"trials":640,"activeCount":69},[],{"trials":642,"activeCount":69},[],{"trials":644,"activeCount":69},[],{"intervention":638,"totalTrials":84,"cells":646},{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":648,"activeCount":69},[],{"trials":650,"activeCount":69},[],{"trials":652,"activeCount":69},[653],{"nctId":629,"briefTitle":630,"status":312,"phases":654,"primaryCompletion":632,"completion":632,"start":633,"enrollment":634,"conditions":655,"interventions":656},[60],[636],[620,638],{"trials":658,"activeCount":69},[],{"trials":660,"activeCount":69},[],{"trials":662,"activeCount":69},[],{"intervention":664,"totalTrials":84,"cells":665},"Hydrochlorothiazide",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":667,"activeCount":69},[],{"trials":669,"activeCount":69},[670],{"nctId":671,"briefTitle":672,"status":312,"phases":673,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":679},"NCT04654312","Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)",[59],"2021-07-22","2021-01-18",30,[678],"Photosensitivity",[664],{"trials":681,"activeCount":69},[],{"trials":683,"activeCount":69},[],{"trials":685,"activeCount":69},[],{"trials":687,"activeCount":69},[],{"intervention":689,"totalTrials":84,"cells":690},"AAT",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":692,"activeCount":69},[],{"trials":694,"activeCount":69},[],{"trials":696,"activeCount":69},[],{"trials":698,"activeCount":69},[],{"trials":700,"activeCount":69},[],{"trials":702,"activeCount":69},[703],{"nctId":704,"briefTitle":705,"status":312,"phases":706,"primaryCompletion":707,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":711},"NCT04799873","Alpha-1-Antitrypsin-Deficiency in COVID-19",[],"2020-12-01","2020-04-08",10,[15],[689],{"intervention":713,"totalTrials":84,"cells":714},"B-vitamin complex",{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":716,"activeCount":69},[],{"trials":718,"activeCount":69},[],{"trials":720,"activeCount":69},[],{"trials":722,"activeCount":69},[],{"trials":724,"activeCount":69},[],{"trials":726,"activeCount":69},[727],{"nctId":728,"briefTitle":729,"status":312,"phases":730,"primaryCompletion":731,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":738},"NCT01095211","B-vitamins Treatment for Improvement of Cognitive Function",[63],"2005-09","2009-12","2003-01",79,[736,737],"Cognitive Function","Metabolic Improvements",[713],{"intervention":740,"totalTrials":84,"cells":741},"diuretics, inotropica",{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":750,"NA":752},{"trials":743,"activeCount":69},[],{"trials":745,"activeCount":69},[],{"trials":747,"activeCount":69},[],{"trials":749,"activeCount":69},[],{"trials":751,"activeCount":69},[],{"trials":753,"activeCount":69},[754],{"nctId":755,"briefTitle":756,"status":312,"phases":757,"primaryCompletion":758,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":765},"NCT00837889","Cognitive Impairment in Patients With Heart Failure",[],"2010-11","2011-05","2009-01",60,[763,764],"Heart Failure","Cognitive Impairment",[740],{"intervention":767,"totalTrials":84,"cells":768},"Vancomycine",{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":770,"activeCount":69},[],{"trials":772,"activeCount":69},[],{"trials":774,"activeCount":69},[],{"trials":776,"activeCount":69},[],{"trials":778,"activeCount":69},[],{"trials":780,"activeCount":69},[781],{"nctId":782,"briefTitle":783,"status":784,"phases":785,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT05651464","Impact of Prophylactic Antibiotics on Bloodstream Infections After Liberation From Extracorporeal Membrane Oxygenation","UNKNOWN",[63],"2023-12-31","2023-01-01",42,[790],"Catheter-Related Infections",[767]]